Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 4/20 | 0.32 |
| ▸ | GLP1R | P43220 | 6/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328241 | 0.87 | MEN1 (0.53) | MEN1KMT2ADPP4DPP8DPP9 | |
| SCHEMBL23945215 | 0.83 | MEN1 (0.49) | MEN1KMT2AUSP2TSHRGLP1R | |
| SCHEMBL13360503 | 0.82 | MEN1 (0.54) | MEN1KMT2ADPP4DPP8DPP9 | |
| SCHEMBL25827160 | 0.81 | MEN1 (0.53) | MEN1KMT2ACA2USP2TSHR | |
| SCHEMBL25466881 | 0.81 | MEN1 (0.53) | MEN1KMT2ACA2USP2TSHR | |
| SCHEMBL25123484 | 0.80 | MEN1 (0.49) | MEN1KMT2AUSP2TSHRTLR2 | |
| SCHEMBL16421153 | 0.79 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL7300946 | 0.79 | MEN1 (0.58) | MEN1KMT2ADPP4DPP8DPP9 | |
| SCHEMBL19324447 | 0.78 | MEN1 (0.52) | MEN1KMT2ADPP4DPP8DPP9 | |
| SCHEMBL17853874 | 0.78 | KMT2A (0.66) | MEN1KMT2ACA2USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | MEN1 1057/4885KMT2A 2228/4885DPP4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.